European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

M Baccarani, MW Deininger, G Rosti… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

M Baccarani, J Cortes, F Pane… - Journal of clinical …, 2009 - ascopubs.org
Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

J Hasford, M Baccarani, V Hoffmann… - Blood, The Journal …, 2011 - ashpublications.org
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the
introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML …

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

L Kalmanti, S Saußele, M Lauseker, MC Müller… - Leukemia, 2015 - nature.com
Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid
leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have …

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib …

R Hehlmann, MC Müller, M Lauseker… - Journal of clinical …, 2014 - ascopubs.org
Purpose Deep molecular response (MR4. 5) defines a subgroup of patients with chronic
myeloid leukemia (CML) who may stay in unmaintained remission after treatment …

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia

R Hehlmann, M Lauseker, S Jung-Munkwitz… - Journal of clinical …, 2011 - ascopubs.org
Purpose Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400
mg/d can be unsatisfactory. Optimization of treatment is warranted. Patients and Methods In …

Diagnosis and treatment of chronic myeloid leukemia in 2015

PA Thompson, HM Kantarjian, JE Cortes - Mayo Clinic Proceedings, 2015 - Elsevier
Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML …

R Hehlmann, M Lauseker, S Saußele, M Pfirrmann… - Leukemia, 2017 - nature.com
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with
imatinib (IM) at 400 mg/day (n= 400) could be optimized by doubling the dose (n= 420) …

A review of the European LeukemiaNet recommendations for the management of CML

M Baccarani, F Castagnetti, G Gugliotta, G Rosti - Annals of hematology, 2015 - Springer
Several guidelines and recommendations on the management of chronic myeloid leukemia
(CML) have been prepared by several scientific societies. The European LeukemiaNet …

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

S Branford, DT Yeung, WT Parker… - Blood, The Journal …, 2014 - ashpublications.org
In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …